4D Molecular Therapeutics · 2 days ago
Principal Data Scientist - Statistical Programming
Wonder how qualified you are to the job?
BiotechnologyGenetics
Insider Connection @4D Molecular Therapeutics
Responsibilities
Provide statistical programming support to assigned projects, including generating programming codes for in-house data analysis
Work closely with biostatisticians to review the SAP and develop data/analysis program specifications
Maintain complete and auditable programming documentation for analysis of clinical trials
Contribute to the development, documentation, and maintenance of reusable programming code library
Collaborate with IT to set up/maintain the statistical computing infrastructure (e.g., SAS server)
Act as a biostatistician on small-scale projects
Collaborate with various functions to ensure robust CRF/EDC development and quality data collection for clinical trials
Oversee biometrics vendors to ensure quality statistical deliverables
Provide quality review of outsourced statistical deliverables and coordinate in-house review comments
Contribute to the development of functional-level standards, SOPs, work instructions, and templates
Represent both biostatistics and statistical programming on study/project teams
Stay abreast of industry developments in biostatistics/statistical programming fields and apply to appropriate systems and processes
Perform other duties as assigned
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
12 + years of related experience with a Bachelor’s degree; or 8 years and a Master’s degree; or a PhD with 5 years experience; or equivalent experience
Work experience in biotech/pharmaceutical industry or medical research for a minimum of 8 years (or 4 years for a PhD with relevant training)
Experience in clinical development
Strong SAS programming skills required with proficiency in SAS/BASE, SAS Macros, SAS/Stat and ODS (proficiency in SAS/SQL, SAS/GRAPH or SAS/ACCESS is a plus)
Good understanding of standards specific to clinical trials such as CDISC, SDTM, and ADaM, MedDRA, WHODRUG
Experience with all clinical phases (I, II, III, and IV) is strongly desirable
Experience with BLA/IND submissions is strongly desirable
Good understanding of regulatory requirements for submission-related activities (e.g., CDISC, CDASH, eCTD) and CRT packages (e.g., XPTs Define/xml, reviewer’s guide, analysis metadata report, executable programs) is desirable
Knowledge of applicable GCP/FDACHMP//ICH/HIPPA regulations
Proficiency in Microsoft Office Apps, such as WORD, EXCEL, and PowerPoint (familiar with the “Chart” features in EXCEL/PowerPoint a plus)
Displays excellent organization and time management skills, excellent attention to detail, and ability to multi-task in a fast-paced environment with shifting priorities and/or conflicting deadlines
Excellent written and verbal communication skills and strong team player with a demonstrated track record of success in a cross-functional team environment
Proven conceptual, analytical, and strategic thinking
Good interpersonal and project management skills
Proactively identifies risks, issues, and possible solutions
Preferred
Experience in ophthalmology and/or biologic/gene therapy a plus
Able to run the P21 checks is a plus
Proficiency in R programming is a plus
Proficiency in SAS/SQL, SAS/GRAPH or SAS/ACCESS
Proficiency in R programming
Company
4D Molecular Therapeutics
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
H1B Sponsorship
4D Molecular Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Trends of Total Sponsorships
2022 (2)
2021 (4)
Funding
Current Stage
Public CompanyTotal Funding
$595MKey Investors
Viking Global InvestorsCystic Fibrosis Foundation
2024-02-06Post Ipo Equity· $300M
2023-05-04Post Ipo Equity· $120M
2020-12-10IPO· nasdaq:FDMT
Leadership Team
Recent News
2024-06-04
2024-06-04
Yahoo Finance
2024-06-04
Company data provided by crunchbase